Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Editors Pick
    • Opioid addicts turning...

    Opioid addicts turning to loperamide to get high

    Written by Medha Baranwal Baranwal Published On 2018-10-15T20:20:05+05:30  |  Updated On 23 Aug 2021 5:57 PM IST

    According to reports Opioid addicts in US have turned to a dangerous and potentially deadly measure: taking loperamide, a common diarrhoea medicine to get high. The misuse of Loperamide, which is sold under the brand name Imodium, could lead to lethal results.


    When addicts don't get the prescriptions they use to be getting because of the crackdown on opioids, they resort to using loperamide. The addicts at times are also scared about the situation with heroin and fentanyl in the streets.


    Too many Imodium caplets may produce a euphoric feeling but it disrupts electrical pathways of heart and at extremely high doses it can cause QTc prolongation and other fatal arrhythmia.The cases of overdose have been recently published in the Annals of Emergency Medicine involving use of loperamide by opioid addicts.


    The US Food and Drug Administration (FDA) has been issuing a safety warning from time to time against loperamide available as a prescription or over-the-counter (OTC) medication.


    Imodium is approved to control symptoms of diarrhoea, including travellers' diarrhoea. In June 2016, the FDA issued a warning about the risk of serious heart problems with high doses of loperamide, including high doses from abuse and misuse. Now, the agency is working to change the medication's packaging to encourage safe use.


    Also Read: Importance of ORS in saving children From Diarrhea


    According to FDA, it continues to receive reports of serious heart problems, including severe heart problems and deaths which is linked to higher-than-recommended doses of loperamide. These reports are primarily among those who have intentionally misused or abused loperamide.


    The recommended maximum dose for adults is 8 milligrams per day for OTC use and 16 mg per day for prescription use. Loperamide is safe when taken as directed. Loperamide can be found OTC under the brand name Imodium A-D, as well as under other store brands and as a generic.


    As a result of these continued reports, the FDA was working with manufacturers to implement blister packs or a type of single-dose packaging and reduce the number of doses in a package — all in the hope of encouraging safe use.


    Also Read: Loperamide use :Safety announcement issued by USFDA

    Patients and consumers should only take loperamide as directed by a health care professional or by the OTC drug label. Taking more than prescribed or more than the recommended dose can lead to severe heart problems or even death.


    When taking OTC loperamide, if your diarrhoea lasts for more than two days, stop taking the medicine and contact your healthcare professional.


    In light of such recent case reports and increased loperamide abuse, the FDA has issued a new safety warning for loperamide regarding its toxic effect on the heart.It has been recommended that Doctors must urge pharmacists and family members to be suspicious and ask questions of anyone buying large amounts of Imodium or similar products.


    For further reference log on to :


    Eggleston W, Clark KH, Marraffa JM. Loperamide abuse associated with cardiac dysrhythmia and death. Ann Emerg Med. 2016 Apr 26. pii: S0196-0644(16)30052-X. doi: 10.1016/j.annemergmed.2016.03.047.


    FDA Drug Safety Communication: FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium), including from abuse and misuse [06-07-2016]. Available from:










    diarrheaDiarrhoeadoseDrugfatalFDAFood and Drug AdministrationhighImodiumloperamidemedicationMedicinemisuseOTCover-the-countersafetywarning
    Source : press release

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok